Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML

NCT04599452 is registered in ClinicalTrials.gov with The Second Hospital of Shandong University as lead sponsor.

NCT NCT04599452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04599452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML
Lead sponsor
The Second Hospital of Shandong University
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 1, 2020
Completion date
December 30, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, elderly, recurrent, refractory